Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Antipsychotic
Ralmitaront
Другие языки:

    Ralmitaront

    Подписчиков: 0, рейтинг: 0
    Ralmitaront
    Ralmitaront.svg
    Clinical data
    Other names RG-7906; RO-6889450
    Identifiers
    • 5-Ethyl-4-methyl-N-[4-[(2S)-morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    KEGG
    ChEMBL
    Chemical and physical data
    Formula C17H22N4O2
    Molar mass 314.389 g·mol−1
    3D model (JSmol)
    • CCC1=C(C(=NN1)C(=O)NC2=CC=C(C=C2)[C@H]3CNCCO3)C
    • InChI=1S/C17H22N4O2/c1-3-14-11(2)16(21-20-14)17(22)19-13-6-4-12(5-7-13)15-10-18-8-9-23-15/h4-7,15,18H,3,8-10H2,1-2H3,(H,19,22)(H,20,21)/t15-/m1/s1
    • Key:XHHXGKRFUPEPFM-OAHLLOKOSA-N

    Ralmitaront (INN, USAN; developmental code names RG-7906 and RO-6889450) is an investigational antipsychotic drug which is undergoing a clinical trial for the treatment negative symptoms in schizophrenia and schizoaffective disorder. Another clinical trial targeting acute psychotic symptoms of schizophrenia has been terminated due to lack of efficacy. It is a partial agonist of the TAAR1. The medication is being developed by the pharmaceutical company Hoffmann-La Roche. Ralmitaront had completed phase 1 clinical trials.

    See also


    Новое сообщение